No Detail Found!

Intralesional Triamcinolone Acetonide Versus Topical Betamethasone Valearate in the Management of Localized Alopecia Areata.

Author(s)
Mona Devi Department of Dermatology, PNS Shifa Hospital, Karachi, Pakistan
Ajmal Rashid Department of Dermatology, PNS Shifa Hospital, Karachi, Pakistan
Rabia Ghafoor Department of Dermatology, Jinnah Postgraduate Medical Center (JPMC), Karachi, Pakistan
Abstract
Objective: To compare the efficacy of intralesional triamcinolone and topical betamethasone in the management of localized alopecia areata. Study Design: A randomized trial. Place and Duration of Study: Dermatology OPD, PNS Shifa Hospital, Karachi, from January to June 2013. Methodology: Patients aged 18 - 50 years with localized alopecia areata were included in the study. Exclusion criteria were more than three patches and those on already steroid or immunosuppressive therapy. Patients were randomly allocated in two treatment groups: Group A received intralesional triamcinolone acetonide (10 mg/ml) and Group B received topical betamethasone valearate cream 0.1% twice daily. Final outcome was ascertained as re-growth of hair on 12th week of follow-up and labelled as efficacy. The data was entered and analyzed using SPSS version 11. Relevant descriptive statistics were calculated. Chi-square test was used to compare efficacy of hair re-growth in both groups. P-value < 0.05 was considered significant. Results: A total of 226 patients were enrolled, 113 in each group. The mean age was 34.36 ±8.7 years. One hundred and sixty-four (72.6%) were males and 62 (27.4%) were females with male to female ratio of 2.6:1. Hair re-growth was seen in 84 (74.3%) of the intralesional steroid group and in 53 (46.9%) of the topical betamethasone group (p < 0.001), which was a significant difference. Conclusion: Intralesional triamcinolone had a better efficacy in the treatment of localized alopecia areata as compared to topical betamethasone valearate.
Publication Details
Page(s) 860-862
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 25, Issue: 12, Year: 2015

Request the full text from PASTIC

References
WassermanD,SanchezD,ScottK,McMichealA, 2007.Alopecia areata,Int J Dermatol 46 121 -31
Taisuke,YoshikiI, 2011.The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata,Exp Dermatol 11 787 -91
MessengerAG,BurnsT,BreathnachS,CoxN,GriffithsC,Wiley-Blackwell Publishing, 2010.Rook's textbook of dermatology, 31 -66
Galan-GutierrezM,Rodriguez-BujaldonA,Moreno-GimenezJC, 2009.Update on the treatment of alopecia areata,Adv Dermatol 100 266 -76
AlkhalifaA, 2011.Topical and intralesional therapies for alopecia areata,Dermatol Ther 24 355 -63
OtbergN., 2011.Systemic treatment for alopecia areata,Dermatol Ther 24 320 -5
ThomasEA,KadyanRS, 2008.Alopecia areata and autoimmunity: a clinical study,Indian J Dermatol 53 70 -4
Al-MultairiN,EldinON., 2011.Clinical profile and impact on quality of life: seven years experience with patients of alopecia,Indian J Dermatol Venerol Leprol 77 489 -93
KumaresanM., 2010.Intralesional steroids for alopecia areata,Inter J Tricholol 2 63 -5
KuldeepCM,SinghalH,KhareAK,MittalA,GuptaLK,GargA, 2011.Randomized comparison of topical betamethasone valearate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata,Inter J Trichol 3 20 -24
QiS,XuF,ShengY,YangQ, 2015.Assessing quality of life in alopecia areata patients in China,Psychol Health Med 20 97 -102
MasmoudiJ,SellamiR,OualiU,MnifL,FekiI,AmouriM, 2013.Quality of life in alopecia areata: a sample of Tunisian patients,Dermatol Res Pract 983804 -
PriceVH, 1991.Alopecia areata; clinical aspects,J Invest Dermatol 96 68S -
DrakeLA,CeilleyRI,CornelisionRL,DobesWL,DornerW,GoltzRW, 1992.Guidelines of care for alopecia areata,J Am Acad Dermatol 26 247 -50
AlkhalifahA,AlsantaliA,WangE,McElweeKJ,ShapiroJ, 2010.,Alopecia areata update: Part II. Treatment. J Am Acad Dermatol 62 191 -202
HordinskyM,DonatiA, 2014.Alopecia areata: an evidence-based treatment update,Am J Clin Dermatol 15 231 -46
MancusoG,BalducciA,CasadioC,FarinaP,StaffaM,ValentiL, 2003.Efficacy of betamethasone valearate foam formulation in comparison with betamethasone dipropionate lotion in treatment of mild to moderate alopecia areata: multicentric, prospective, randomized, controlled, investigator -blinded trial,Int J Dermatol 42 572 -5
TostiA,IorizzoM,BottaGL,MilaniM. Efficacy, 2006.and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized double blind placebo controlled trial,J Euro Acad Dermatol Venereol 20 1243 -7
2006.Prescriber update,Topical steroids and skin damage. WHO Drug Inf Bull 20 1 -
PorterD,BurtonJL, 1971.Comparison of intralesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata,Br J Dermatol 85 272 -3
0

Citations

0

Downloads

83

Views